1 |
Uchigasaki et al. (1992) [3] |
52/F |
Anal ulcer and pruritus for 2 yra
|
Anal canal SRCC progressed from adenocarcinoma in situ of anal glands or mucinous glands (1.5 cm), Pagetoid spread (7 cm) |
pCEA+ mCEA+ mucicarmine+ PAS+ D-PAS-resistant |
T1N3M0, stage IIIB |
Topical 5-FU cream, EB, ASR |
Recurrence with systemic metastasis and died (7 mo) |
2 |
Morihisa et al. (1999) [7] b
|
75/F |
Perianal erythema and erosion for 7 mo |
Anal canal SRCC (size not described), Pagetoid spread (5 cm) |
CEA+ mucicarmine+ PAS+ |
N3M1, stage IV |
Nephrostomy for ARF due to systemic metastasis |
Systemic metastasis and died (4 mo) |
3 |
Nagano et al. (1999) [8] |
46/F |
Inguinal LN enlargement |
Anal canal and rectal SRCC (3.5 cm), Pagetoid spread (7.5 cm) |
Alcian blue+ PAS+ |
T2N3M0, stage IIIB |
APR, CTX (5-FU, LV) |
NR (3 mo) |
4 |
Naganuma et al. (2004) [9] |
85/F |
Anal bleeding for 3 yr |
Anal canal SRCC (unknown size of polyp, residual anal canal mass, 5 mm), Pagetoid spread (size not described) |
CEA+ CA19-9+ CK20+ CK7– GCDFP-15– |
N3M1, stage IV |
Anal polypectomy with CTX (5-FU), RT |
Systemic metastasis and died (25 mo) |
5 |
Nishimura et al. (2004) [10] b
|
76/F |
Anal erosion and etythema for 2 yr |
Anal canal SRCC (size not described), Pagetoid spread (6 cm) |
CK20+ GCDFP-15- |
Not availableb
|
APR, CTX (5-FU, cisplatin) |
NR (5 mo) |
6 |
Yoshitani et al. (2009) [11] |
50/M |
Axillary and inguinal LN enlargement for 1 mo, erythematous perianal skin |
Anal canal SRCC (size not precisely described; anal verge to dentate line), Pagetoid spread (size not described) |
CK20+MUC-1+CK7- |
N3M1, stage IV |
CTX (bevacizumab/mFOLFOX6, FOLFIRI) |
Alive with CR evaluated by PET-CT (6 mo) |
7 |
Ikezawa et al. (2010) [12] |
53/M |
Anal pruritus for 22 mo |
Anal canal SRCC (1 cm), Pagetoid spread (2 cm) |
pCEA+ CK20+ CK7– GCDFP-15– |
T1N2M0, stage IIIB |
APR, CTX (uracil-tegafur, LV, mFOLFOX6) |
Recurrence with systemic metastasis and died (9 mo) |
8 |
Ioannidis et al. (2012) [4] |
87/F |
Anal discomfortness and pain for 8 mo |
Anal canal SRCC (3 cm) |
Not done |
T2N0M0, stage II |
Wide excision with chemotherapy (5-FU) and RT |
NR (6yr) |
9 |
Terada (2014) [5] |
49/M |
Anal bleeding |
Anal canal SRCC (< 2 cm) |
AE1/3+ CK8+ CK19+ CEA+ CA19-9+ synaptophysin+ CDX2+ MUC1+ MUC2+ EMA+ CK7– CK20– CK5/6– MUC5AC– MUC6– CD56– NSE– chromogranin– vimentin– |
T1N1M0, stage IIIA |
Miles’ operation with LN dissection |
Metastatic carcinomatosis and died (5 mo) |
10 |
Kim et al. (2016) |
61/F |
Erythematous perianal and vulvar skin for 3 yr, synchronous colon adenocarcinoma (0.2 cm) |
Anal canal SRCC (4 cm), Pagetoid spread (8.2 cm) |
pCEA+ CK20+ CK19+ MOC-31+ CDX2– CK7– HMB45– mucicarmine+ |
T2N3M0, stage IIIB |
Extended Miles’ operation and inguinal LN dissection, CTX (5-FU, MTC), RT (planned) |
NR (2 mo) |